MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414090 | Name: Spiroplatin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Spiroplatin is an Antineoplastic. Spiroplatin induces DNA cross-linking, thereby inhibiting DNA replication and the synthesis of RNA and protein.

Chemical Structure

Spiroplatin
Spiroplatin
CAS# 74790-08-2

Theoretical Analysis

MedKoo Cat#: 414090

Name: Spiroplatin

CAS#: 74790-08-2

Chemical Formula: C8H18N2O4PtS

Exact Mass: 433.0635

Molecular Weight: 433.39

Elemental Analysis: C, 22.17; H, 4.19; N, 6.46; O, 14.77; Pt, 45.01; S, 7.40

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Spiroplatin; CCRIS3649; CCRIS-3649; CCRIS 3649
IUPAC/Chemical Name
(Cyclohexane-1,1-diylbis(methylamine)-N,N')(sulphato(2-)-O,O')platinum
InChi Key
XASGSSXPZXRXFL-UHFFFAOYSA-L
InChi Code
InChI=1S/C8H18N2.H2O4S.Pt/c9-6-8(7-10)4-2-1-3-5-8;1-5(2,3)4;/h1-7,9-10H2;(H2,1,2,3,4);/q;;+2/p-2
SMILES Code
O=S1(O[Pt]2([NH2]CC3(C[NH2]2)CCCCC3)O1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 433.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tanis BC, Vermorken JB, ten Bokkel Huinink WW, van Oosterom AT, Splinter TA, Vendrik KJ, Sleijfer DT, van der Burg ME, van der Putten E, Pinedo HM. Multicenter phase II study of spiroplatin. Oncology. 1992;49(2):99-103. doi: 10.1159/000227020. PMID: 1574259. 2: Tanis BC, Vermorken JB, ten Bokkel Huinink WW, Klein I, Gall H, van Oosterom AT, Simonetti G, McVie JG, van der Vijgh WJ, Pinedo HM. Phase I study of spiroplatin. Eur J Cancer. 1991;27(3):268-73. doi: 10.1016/0277-5379(91)90513-d. PMID: 1827311. 3: van der Vijgh WJ, Elferink F, Vermorken JB, ten Bokkel Huinink WW, Klein I, Gall HE, Simonetti G, McVie JG, Pinedo HM. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial. Eur J Cancer Clin Oncol. 1988 Apr;24(4):621-7. doi: 10.1016/0277-5379(88)90290-8. PMID: 3383966. 4: Schroyens WA, Meeker JB, Dodion P, Stryckmans PA, Rozencweig M. Comparative effect of cisplatin, spiroplatin, carboplatin, iproplatin and JM40 in a human myeloid clonogenic assay. Eur J Cancer Clin Oncol. 1988 Aug;24(8):1309-12. doi: 10.1016/0277-5379(88)90221-0. PMID: 3053206. 5: Schroyens W, Dodion P, Rozencweig M. Comparative effect of cisplatin, spiroplatin, carboplatin and iproplatin in a human tumor clonogenic assay. J Cancer Res Clin Oncol. 1990;116(4):392-6. doi: 10.1007/BF01612923. PMID: 2202731. 6: Boven E, van der Vijgh WJ, Nauta MM, Schlüper HM, Pinedo HM. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res. 1985 Jan;45(1):86-90. PMID: 4038381. 7: Schurig JE, Schlein A, Florczyk AP, Farwell AR, Bradner WT. Animal models for evaluating the myelosuppressive effects of cancer chemotherapeutic agents. Exp Hematol. 1985;13 Suppl 16:101-5. PMID: 3987834. 8: Offerman JJ, Meijer S, Mulder NH, Sleijfer DT, Bijster P, Hellendoorn HB, Donker AJ, van der Hem GK. Nephrotoxicity of 1,1-diaminomethylcyclohexane sulphato platinum II (spiroplatin; TNO-6). Eur J Cancer Clin Oncol. 1985 Apr;21(4):447-51. doi: 10.1016/0277-5379(85)90035-5. PMID: 3891361. 9: Elferink F, van der Vijgh WJ, Pinedo HM. Analysis of antitumour [1,1-bis(aminomethyl)cyclohexane]platinum(II) complexes derived from spiroplatin by high-performance liquid chromatography with differential pulse amperometric detection. J Chromatogr. 1985 Mar 1;320(2):379-92. doi: 10.1016/s0021-9673(01)90516-3. PMID: 4030937. 10: Sanderson BJ, Ferguson LR, Denny WA. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat Res. 1996 Aug 17;355(1-2):59-70. doi: 10.1016/0027-5107(96)00022-x. PMID: 8781577.

View History

BMP-22

BMP-22

Featured